Abstract
This review summarizes the structure and function of the alveolar unit, comprised of alveolar macrophage and epithelial cell types that work in tandem to respond to infection. Granulocyte-macrophage colony-stimulating factor (GM-CSF) helps to maintain the alveolar epithelium and pulmonary immune system under physiological conditions and plays a critical role in restoring homeostasis under pathologic conditions, including infection. Given the emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and global spread of coronavirus disease 2019 (COVID-19), with subsequent acute respiratory distress syndrome, understanding basic lung physiology in infectious diseases is especially warranted. This review summarizes clinical and preclinical data for GM-CSF in respiratory infections, and the rationale for sargramostim (yeast-derived recombinant human [rhu] GM-CSF) as adjunctive treatment for COVID-19 and other pulmonary infectious diseases.
1 Introduction
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a global health crisis emphasizes the importance of understanding the coordination and crosstalk between alveolar epithelial cells (AECs) and alveolar macrophages (AMs) in maintaining lung physiology during viral illness (Lang et al., 2020). Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an immune-modulating cytokine that plays a critical role in maintaining the alveolar epithelium and pulmonary immune system under homeostatic and pathologic conditions, including infection (Rosler and Herold, 2016; Lang et al., 2020). GM-CSF drives AM differentiation and homeostasis and maintains the integrity of the lung epithelium under near-constant exposure to inhaled pathogens (Trapnell and Whitsett, 2002; Rosler and Herold, 2016). In response to external insult, GM-CSF facilitates and accelerates the epithelial wound-healing process, driving the immune functions of the AMs and the repair processes initiated in the alveolar epithelium, including restoration of barrier function, and facilitating a return to homeostasis (Rosler and Herold, 2016).
2 Functions of the Alveolus
2.1 Maintaining Alveolar Homeostasis
The alveolar epithelium is essential for gas exchange in the lung and serves as a physical barrier between the lumen and the underlying submucosa (Guillot et al., 2013). The alveolar epithelium accounts for 99% of the surface area of the lung and is continually bombarded by external insults, such as inhaled particulates and pathogens (Guillot et al., 2013). Maintaining alveolar homeostasis and protecting the integrity and function of the epithelial layer requires the dynamic orchestration of multiple cell types, including type I and type II AEC (AECI, AECII, respectively) and alveolar macrophages, as well as processes such as repair and regeneration, surfactant homeostasis, and pathogen clearance and defense (Figure 1A) (; Mason, 2006; Guillot et al., 2013).
FIGURE 1
Maintaining the integrity of the alveolar epithelium is a key function of alveolar tight junctions that seal the lateral space between adjacent AECs and control the passage of molecules between the alveolar lumen and interstitial compartment to help defend against infection (Guillot et al., 2013; Short et al., 2016; Wittekindt, 2017). Pathogens that target the alveolar epithelium can interfere with tight junctions; for example, respiratory viruses such as influenza have evolved mechanisms to disrupt or alter tight junctions (Short et al., 2016). Pseudomonas aeruginosa has also been shown to cause disruption of tight junctions in patients with cystic fibrosis (Higgins et al., 2016), and Aspergillus fumigatus proteases damage the respiratory epithelial barrier, leading to the loss of tight junctions (Knutsen et al., 2002).
2.2 Alveolar Epithelial Cells and Inflammation
AECI comprise 96% of the surface of the lung and are critical to gas exchange (Guillot et al., 2013). AECI are flat, thin cells that have substantial interaction with AMs and neighboring AECs, including those in adjacent alveoli (Guillot et al., 2013). Although AECI do not readily repair or proliferate, they can initiate the innate immune response (Yamamoto et al., 2012; Guillot et al., 2013). Pneumococcal pneumonia induces expression of CXCL5 and pattern recognition receptors TLR2 and STING (Yamamoto et al., 2012). The observed induction of innate immune responses in AECI and expression of toll-like receptors (TLR) through proinflammatory cytokines suggest a role for AECI in innate immune response initiation (Wong et al., 2012; Yamamoto et al., 2012; Guillot et al., 2013).
AECII are dynamic cells similar in number to AECI but account for far less surface area due to their cuboidal shape (Guillot et al., 2013). AECII contribute to pulmonary homeostasis by secreting surfactant and key surfactant proteins that participate in pathogen clearance (). Expression of a variety of receptors helps AECII monitor the alveolar niche and produce cytokines and other signaling molecules (). AECII are able to proliferate and act as progenitors to replace old or damaged AECI cells (). Interaction between AM-derived immune mediators and signals from other AECs helps promote and regulate AECII proliferation and differentiation ().
2.3 Macrophages of the Alveolus
Tissue-resident AMs are the predominant macrophages under physiological conditions within the lumen of the alveolus and the interstitial macrophages between alveoli (Tan and Krasnow, 2016). As the resident-dedicated phagocyte, AMs interact with both the innate and acquired immune systems, protecting the alveoli from inhaled pathogens (Trapnell and Whitsett, 2002; ). AMs interact with AECs of both types to maintain alveolar homeostasis ().
Efferocytosis is a constitutive function of macrophages required for maintaining immune homeostasis in health and during inflammatory responses (; McDonald et al., 1999; Ortega-Gomez et al., 2013) and is also an important antimicrobial effector mechanism to regulate intracellular pathogens (; Martin et al., 2014). AMs are responsible for the clearance of apoptotic neutrophils through efferocytosis, the process through which apoptotic cells are removed without release of their contents (Ortega-Gomez et al., 2013; ). Defective efferocytosis results in chronic inflammation and significantly increases the likelihood of developing lung injury (; McDonald et al., 1999). Efferocytosis is a major contraction mechanism for the recruited macrophage pool following acute lung injury (ALI) (Janssen et al., 2011). This scenario is unique to the lungs because the alveoli and conducting airways are extraepithelial and communicate directly with the external environment. In the lung, efferocytosis can be performed by dedicated phagocytes, such as AMs and dendritic cells (DCs), and to a lesser extent by airway epithelial cells (). In animal models, exposure to second-hand smoke impaired the ability of AMs to perform phagocytic activities, including efferocytosis. Delivery of intranasal recombinant murine GM-CSF restored AM function and improved host defense, conferring protection against pneumonia (Subramaniam et al., 2016).
Monocyte-derived AMs may be recruited and differentiated from monocytes upon lung injury or infection (Morales-Nebreda et al., 2015). Investigators have long thought that AMs originate from circulating blood monocytes, based on their observations that bone marrow-derived monocytes can replenish the AM pool after lethal irradiation or in response to injury (Morales-Nebreda et al., 2015). In response to AM injury or depletion, monocytes are recruited to the lung and differentiate into AMs (Misharin et al., 2017; Joshi et al., 2020), where they may replace the tissue-resident AM population over time (Morales-Nebreda et al., 2015). The degree to which resident AMs are replaced by persistent monocyte-derived AMs depends on several factors: the extent of AM depletion, the intensity of inflammation, and the ability of monocytes to reach the niche. During mild infections associated with a small reduction in resident macrophages, very few monocytes will engraft into the resident macrophage pool as proliferation of resident macrophages is usually sufficient ().
2.4 Alveolar Epithelial Cell and Alveolar Macrophage Crosstalk
It is well-established that AECs and AMs communicate via autocrine and/or paracrine signaling to promote epithelial repair following injury. While particle exposure of AM-AEC co-cultures induces release of GM-CSF, TNFα, and macrophage inflammatory proteins (e.g., MIP-1β and MIP-2), AM or AEC monocultures, or fibroblast co-cultures of either AMs or AECs do not (Tao and Kobzik, 2002; Ishii et al., 2005). During pulmonary infection with Legionella, AECII enable communication between AMs and recruited myeloid cells (Liu et al., 2020). Infected AMs cannot produce the cytokines needed to control the infection. However, IL-1 released by infected macrophages induces AECII to produce GM-CSF, which in turn metabolically reprograms monocytes, promoting host defense (Liu et al., 2020). Epithelial cell-derived GM-CSF improves host-defense function by reprogramming monocytes to generate the cytokines needed to control infection (Liu et al., 2020); therefore, via AM/AECII crosstalk, GM-CSF signaling helps to orchestrate pulmonary immune response.
3 Pulmonary Response to Inhaled Pathogens
3.1 Overview of Pulmonary Acute Lung Injury and Acute Respiratory Distress Syndrome
ALI and acute respiratory distress syndrome (ARDS) have been considered events along a clinical spectrum, although the 2012 Berlin definition does not include a separate definition for the less severe ALI (Costa and Amato, 2013). Triggering events that may result in ALI and ARDS may include exposure to an inhaled chemical or physical agent, such as gases, or viral, bacterial, or fungal pathogens (). Other factors, such as genetic predispositions or comorbidities may magnify the pulmonary insult resulting from the triggering event (). ALI and ARDS are characterized by damage to the alveolar-capillary membrane resulting in excess production of inflammatory molecules, followed by noncardiogenic pulmonary edema and varying degrees of hypoxemia (; ). One of the major hallmarks of ALI/ARDS is AEC injury, for which the receptor for advanced glycation end products (RAGE) has been suggested as a biomarker (Uchida et al., 2006). AECII rapidly proliferate following epithelial injury, with some eventually differentiating into AECI (; Herzog et al., 2008; Guillot et al., 2013). In ALI and ARDS, both AECII and AECI sustain damage, and the lack of viable AECII compromises the repair process, favoring the progression of ALI to ARDS (Pison et al., 1988; ). When massive inflammation cannot be controlled (as happens in ∼50% of cases), fibroblasts are activated in an attempt to repair the lung damage ().
In an experimentally-induced ALI rat model, transplanted AECII reduced early inflammation, promoted recovery of lung function, and reduced mortality (). Moreover, transplantation of AECII dampened inflammatory markers to control levels, demonstrating a reduction in the inflammatory response and significantly decreasing monocyte chemoattractant protein-1 concentrations in lung homogenates (). The proposed mechanism by which AECII reduced injury is through release of prostaglandin E2 (PGE2) and surfactant protein A, thus reprogramming AMs to an anti-inflammatory phenotype (). This further demonstrates the close interplay between the AECs and AMs.
3.2 Pulmonary Response to Infection
Upon lung infection with viruses, bacteria, or fungi, sensor cells such as AECs, AMs, and DCs initiate an immunologic response (Table 1) (Iwasaki et al., 2017). The alveolar response to challenge by pathogens is characterized by how it responds to the presence of infectious agents and how it shapes the response to the newly recruited immune cells. Given that a prolonged or exaggerated immune response can damage the respiratory tract, it is critical to closely monitor and regulate inflammation to maintain an appropriate immune response (Rubins, 2003; Newton et al., 2016).
TABLE 1
| Viral | Bacterial | Fungal | |
|---|---|---|---|
| Common pathogen(s) | Influenza, SARS-CoV-2, RSV, human metapneumovirus (hMPV) | Pseudomonas aeruginosa, Mycobacterium tuberculosis, Staphylococcus aureus | Aspergillus fumigatus, Histoplasma capsulatum |
| Host response to invasion | Influenza
| P. aeruginosa
|
|
Primary COVID-19 infection
| IPA
| ||
| Role of GM-CSF | Influenza
| P. aeruginosa
| A. fumigatus
|
hMPV
| — | — | |
Immune response to common viral, bacterial, and fungal pathogens.
AEC, alveolar epithelial cell; AECII, alveolar epithelial cell type II; AM, alveolar macrophage; ARDS, acute respiratory distress syndrome; CAPA, COVID-19−associated pulmonary aspergillosis; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; DC, dendritic cell; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon gamma; IPA, invasive pulmonary aspergillosis; hMPV, human metapneumovirus; OR, odds ratio; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TB, tuberculosis; TLR, toll-like receptor; TNFα, tumor necrosis factor alpha.
During the initial stages of an infection, tissue-resident innate immune cells recruit circulating neutrophils into the infected tissue, promoting recruitment of monocytes, and in turn, more neutrophils, thus potentiating a proinflammatory environment (Iwasaki et al., 2017). Neutrophil-mediated killing requires the generation and release of toxic compounds; once the infection is cleared, neutrophils undergo apoptosis within tissues and must be rapidly cleared to limit damage to healthy tissue (Ortega-Gomez et al., 2013).
AECs secrete antimicrobial peptides and proinflammatory factors in response to bacterial infection (Li et al., 2012). AMs present within the alveolar space clear airborne particles and pathogens as another roadblock to infection by secreting chemokines to attract neutrophils and monocytes. The pulmonary immune response is fine-tuned via communication between AMs and epithelial cells (Westphalen et al., 2014).
3.3 Role of Alveolar Epithelial Cells in Post-Inflammatory Pulmonary Fibrosis
Damage to the lung’s complex structure is a common characteristic of a variety of interstitial lung diseases that fall under the umbrella of pulmonary fibrosis due to an incomplete wound repair response. Chronic respiratory failure can arise due to lung function impairment from scar formation and defective gas exchange (Mulugeta et al., 2015). Infection and the corresponding inflammatory response and ARDS can result in pulmonary fibrosis (Spagnolo et al., 2020), more specifically, post-inflammatory pulmonary fibrosis which also encompasses post-inhalation, post-drowning, and ventilator-induced injury.
Recent evidence supports the “severity of epithelial injury” hypothesis originally proposed by Haschek and Witschi in 1979 in which delay of epithelial repair, not inflammation, leads to fibroblast proliferation and collagen deposition (Haschek and Witschi, 1979). Lung fibrosis is currently considered a disease of epithelial-fibroblast imbalance, suggesting a pivotal role for AEC dysfunction in the development of a fibrotic lung phenotype (Uhal and Nguyen, 2013). Substantial evidence exists that vulnerable and/or dysfunctional AECII are a pivotal player in aberrant injury/repair responses occurring in pulmonary fibrosis and other forms of fibrotic lung disease.
3.4. Repairing and Restoring Lung Function
The AECs are critical in normalizing lung function since they are both a major target for injury, and intrinsically involved in the repair process. Simple repair could lead to dysfunctional epithelial repopulation due to the development of scar tissue and fibrosis. Aberrant remodeling and differentiation of epithelial cells may culminate in chronic interstitial lung diseases, obstructive diseases, or the late phases of ALI/ARDS. The preferred outcome is therefore successful regeneration where fully functioning epithelial-lined airways and alveolar airspaces are created ().
AECs respond via appropriate repair or inappropriate remodeling, which might include excessive apoptosis, epithelial-mesenchymal transition, or reprogramming to a dysfunctional state of differentiation, leading to abnormal repair and development of fibrotic scarring or abnormal pathology (). While apoptosis is important for shaping inflammatory cell populations, inappropriate AEC apoptosis can lead to deleterious remodeling and respiratory insufficiency () even in the absence of inflammation (Uhal and Nguyen, 2013). AEC apoptosis is sufficient to initiate a process of fibrosis, leading to progressive scarring of the epithelium (Kim et al., 2018) mediated by activated myofibroblasts, the major contributors to fibrotic lung disease (Herzog et al., 2008). Furthermore, phagocytosis of apoptotic AECs by AMs causes a shift towards profibrotic gene expression (Kim et al., 2018).
4 Pulmonary Responses to Viral Infection
AMs play a critical role in controlling respiratory viral infections (RVIs) such as influenza and SARS-CoV-2 to prevent their spread. Here, we focus on the interaction between AECs and AMs in responding to these two viruses. A more comprehensive review of RVIs is denoted in Table 1.
4.1 Influenza Virus Infection
AECs are the primary target for human influenza infection, characterized by loss of alveolar barrier function and edema, with persistent inflammation resulting in greater capillary/alveolar leakage, culminating in severe hypoxemia and ARDS. Following viral clearance and initiation of AEC repair, local progenitor cells replicate, and the integrity of the epithelial layer is restored. Virus elimination and immune-mediated pulmonary injury are balanced by the immune response to minimize respiratory tract damage (Rosler and Herold, 2016).
4.2 SARS-CoV-2 Infection and COVID-19
COVID-19 is caused by SARS-CoV-2, resulting in respiratory illness including pneumonia, ARDS, respiratory failure, shock, multi-organ failure and death in severe cases (Huang et al., 2020; Prompetchara et al., 2020).
SARS-CoV-2 binds to the angiotensin-converting-enzyme 2 receptor via the viral spike protein that is cleaved by proteases to allow fusion of the viral and cellular membranes, and subsequent internalization and release of the viral RNA (Hoffmann et al., 2020). Currently, the exact mechanism by which SARS-CoV-2 injures the lung is not fully understood. The evidence points to direct viral infection of host epithelial and endothelial cells, triggering release of proinflammatory cytokines as well as dysregulation of the renin-angiotensin system (; Wang et al., 2020).
After the virus infects the lining of the nose, bronchi, and bronchioles, it then infects the alveoli in the distal lung, in particular AECII (Mason, 2020). AEC injury appears to be the main cause of COVID-19-related ARDS (Li and Ma, 2020). The alveoli seem to respond to SARS-CoV-2 in a biphasic manner, with initial alveolar flooding and marked hypoxia followed by an inflammatory ARDS-like response (Mason, 2020). In some patients, infection leads to the activation of AMs and the release of proinflammatory cytokines by AECs and AMs (Polidoro et al., 2020). In severe cases, tissue-resident AMs can be depleted, accompanied by an excessive influx of monocyte-derived macrophages (Liao et al., 2020).
Mounting evidence suggests that severe RVIs, especially influenza and SARS-CoV-2, can be complicated by fungal or bacterial coinfection (Table 1) (Tasher et al., 2011; Smith and McCullers, 2014; ; Vaillancourt and Jorth, 2020). Aspergillus airway overgrowth with pulmonary infection is characterized by mixed airway inflammation and bronchial invasion known as COVID-19−associated pulmonary aspergillosis (CAPA) (Marr et al., 2021). The incidence of CAPA has been reported in published studies to be 20–30% of patients with severe COVID-19 requiring mechanical ventilation. Three studies that deployed enhanced prospective screening provided incidence estimates of 14–20% (Marr et al., 2021).
Many patients with COVID-19 contract a secondary bacterial infection which frequently leads to worse outcomes (Vaillancourt and Jorth, 2020). For instance, Feng et al. reported a multicenter study of 476 patients with COVID-19 comparing outcome severity with the absence or presence of a secondary bacterial infection. Critically ill patients had the highest rate of bacterial coinfection (34.5%) compared to moderately (3.9%) and severely (8.3%) ill patients ().
5 GM-CSF Regulation of Alveolar Macrophages and Pulmonary Response to Viral Infections
5.1 Biology of GM-CSF
GM-CSF was first characterized by as a myelopoietic growth factor capable of differentiating bone marrow precursor cells into granulocytes and macrophages. It stimulates proliferation and activation of monocytes, macrophages, DCs, neutrophils, and eosinophils (Hamilton, 2015; ). GM-CSF−deficient mice primarily lack lung AMs, and mice lacking the GM-CSF receptor have markedly reduced numbers of macrophages throughout the body (). GM-CSF supports the development and/or maintenance of bone marrow−derived CD103+ DCs (; Lang et al., 2020) which, in mice, have been shown to be critically important for the initiation of cytotoxic CD8+ T-cell responses in the lung (Lang et al., 2020). GM-CSF thus serves a crucial role in normal lung health and is important for orchestrating a broad range of adaptive immune responses (Lang et al., 2020).
Following its initial discovery, GM-CSF has been identified to have a much broader role as an immune-modulating cytokine, specifically playing a critical role in AM homeostasis, lung inflammation, and immunological disease (Guillot et al., 2013; Lang et al., 2020). GM-CSF regulates the catabolism of surfactant proteins and lipids in the lung (Huffman et al., 1996). The majority of surfactant is catabolized or reutilized by AECII, and AM catabolize or phagocytose the remaining surfactant pool (Trapnell and Whitsett, 2002).
The receptor for GM-CSF is a heterodimer comprised of an α chain that is specific for GM-CSF and a signal-transducing β chain that is shared by IL-3 and IL-5 receptors (). GM-CSF receptor activation triggers activation of JAK2 and STAT5 leading to downstream activation of PI3K signaling, as well as transcription factors, such as PU.1 and peroxisome proliferator-activated receptor-γ (PPARγ) (Figure 1B) (; ; Zhan et al., 2019).
5.2 Sources of Pulmonary GM-CSF
GM-CSF is secreted by a variety of cells, including epithelial cells, endothelial cells, fibroblasts, and a variety of leukocytes (Shi et al., 2006; Lang et al., 2020). Production of GM-CSF in non-hematopoietic cells generally requires a stimulus (Hamilton, 2019). Certain populations of neutrophils, basophils, and eosinophils have been reported to produce GM-CSF. In addition, B cells can produce GM-CSF, particularly after activation, and GM-CSF derived from B cells in the pleural space may have an autocrine signaling role in response to lung infections and sepsis (Harris et al., 2000; Weber et al., 2014; Hamilton, 2019).
T cells, IL-1β, IL-12, and PGE2 in humans have been shown to induce GM-CSF production (Quill et al., 1989; ; Shiomi and Usui, 2015). A variety of T-cell types are important sources of GM-CSF, including Th2, CD4+ T cells, and Th1/17 cells (Shiomi and Usui, 2015). Some studies suggest T cells respond to CD3 blockade by secretion of GM-CSF upon stimulation with anti-CD3 (Shi et al., 2006). Th17 cells may secrete GM-CSF in response to IL-23 (). CD4+ T helper cells have been identified as a cell population that primarily produce GM-CSF (Komuczki et al., 2019; Lang et al., 2020). In certain settings, transcription factors, such as nuclear factor of activated T cells (NFAT) have been shown to be required for GM-CSF production (Shang et al., 1999; Johnson et al., 2004; Shiomi and Usui, 2015). Not surprisingly, given the complexity of cytokine networks, cytokines such as IFN-γ, IL-4, IL-10, may inhibit production of GM-CSF (Shiomi and Usui, 2015). Interplay between activated T cells and macrophages results in inflammatory positive feedback loops influencing production of GM-CSF in macrophages, as well as neighboring resident tissue cells (Shi et al., 2006; Shiomi and Usui, 2015).
Alveolar epithelial cell production of GM-CSF is the major source of pulmonary GM-CSF (). In lung endothelial cells and fibroblasts, TNFα and IL-1β have been shown to induce GM-CSF synthesis and production facilitating autocrine and paracrine activity in the lung (; ; Koga et al., 2016; Hamilton, 2019). GM-CSF produced following a stimulus in endothelial cells and fibroblasts is thought to help guide tissue-invading leukocytes (Hamilton, 2019).
5.3 GM-CSF and Alveolar Epithelial Cells
Baseline expression of GM-CSF in AECs is low, but GM-CSF mRNA expression is constitutively present (Mir-Kasimov et al., 2012; Lang et al., 2020). However, AECII are the major non-hematopoietic, pulmonary source of GM-CSF (). The inherent plasticity of AECII allows them to rapidly express GM-CSF in response to viral infection, or via induction by inflammatory cytokines, such as IL-1β, TNF-α, and in turn, expression of GM-CSF influences AECII plasticity in an autocrine fashion, inducing downstream STAT5 phosphorylation and subsequent upregulation of cyclin D1 and other cell cycle genes that regulate differentiation of AECII into AECI (; Mir-Kasimov et al., 2012; Sturrock et al., 2012).
Overexpression of GM-CSF in transgenic GM-CSF knockout (GM-CSF−/−) mice induced AECII hyperplasia, increasing lung size and demonstrating a role for GM-CSF in the regulation of AECII proliferation and differentiation (Huffman Reed et al., 1997). Overexpression of GM-CSF also enhanced survival of mice in hyperoxia; this effect may be explained by preservation of AEC barrier function and fluid clearance, and at least in part by a reduction in hyperoxia-induced apoptosis of AECs (Paine et al., 2003).
In influenza viral infection, the proinflammatory condition prompts AECII to express GM-CSF and produces high levels of GM-CSF (Rosler and Herold, 2016). AECII also express GM-CSF receptors, facilitating both indirect and autocrine signaling that can spur AECII proliferation and decrease AEC apoptosis (Sturrock et al., 2012). GM-CSF has been shown to decrease AECII susceptibility to oxidative stress injury (Sturrock et al., 2012). GM-CSF increases Mcl-1 expression and subsequent mitochondrial cytochrome c release and induces Akt phosphorylation that was shown to protect AECs against hyperoxia (Sturrock et al., 2012).
AEC-derived GM-CSF can elicit AM activation and expansion, DC migration to lymph nodes, and T cell activation and recruitment to alveoli, resulting in viral clearance and protection from viral infection (Unkel et al., 2012; Rosler and Herold, 2016). Activated resident AMs secrete TNFα and induce AECs to express GM-CSF, initiating AEC proliferation and supporting restoration of alveolar barrier function ().
5.4 Overview of Macrophages and GM-CSF
Macrophages are found in all mammalian tissues and develop together with the organs they populate. Through various scavenger, pattern recognition, and phagocytic receptors, macrophages sense and respond to tissue injury and invasion by infectious organisms. They play a critical role in normal tissue homeostasis, ensuring a balanced response to tissue damage. If this response is not carefully monitored and fine-tuned, inflammatory disease may result (Lavin et al., 2015). The tissue microenvironment tightly regulates the differentiation and homeostasis of macrophage cell types. Macrophage identity and function is shaped by cytokines and metabolites produced in the local environment that drive expression of specific transcription factors (Lavin et al., 2015). Examples of tissue-specific macrophages include microglial cells in the brain, splenic macrophages, Kupffer cells in the liver, and AMs in the lung (Lavin et al., 2015). Macrophages require the continuous provision of trophic factors such as IL-34, macrophage colony-stimulating factor (M-CSF) (also known as colony-stimulating factor [CSF] 1) and GM-CSF (also known as CSF2) for their development and maintenance (Lavin et al., 2015).
Surfactant accumulation impairs gas exchange, resulting in increased susceptibility to microbial infections (Rosler and Herold, 2016). Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by the excessive accumulation of surfactant proteins within alveoli, causing progressive respiratory insufficiency. The pathogenesis associated with aPAP has been attributed to high levels of neutralizing autoantibodies against GM-CSF in the serum and bronchoalveolar lavage fluid (BALF). These autoantibodies neutralize the biologic activity of GM-CSF, impairing the maturation and phagocytosis of AMs and AM-mediated pulmonary surfactant clearance (Tazawa et al., 2010; Ohkouchi et al., 2017).
5.5 GM-CSF and Alveolar Macrophages
In the context of infection, GM-CSF signals growth and differentiation of myeloid cells (granulocytes and macrophages) when more of these cells are needed to fight infection, and governs emergency myelopoiesis, expanding and mobilizing progenitor myeloid cells when needed (Metcalf, 1986; ; Lang et al., 2020). GM-CSF is essential for driving the immune functions of AMs (Figure 1B) (Rosler and Herold, 2016).
Stillborn infants lack AMs, suggesting that these cells develop postnatally, similar to observations in mice (; ). This is likely because, while GM-CSF is expressed during early gestation, AM residence in the alveoli is only established at birth when the lungs are inflated, with subsequent continued maturation well into childhood (). Transforming growth factor-beta (TGFβ) collaborates with GM-CSF to induce the transcription factor PPARγ to drive early AM differentiation and maintenance (Lambrecht, 2017; Yu et al., 2017).
GM-CSF regulates AM differentiation and innate immunity in the lung (Shibata et al., 2001). GM-CSF−/− mice are prone to respiratory infections, and experimental data show that restoring GM-CSF expression reverses this susceptibility. GM-CSF−/− mice have increased susceptibility to bacterial infection due to defective pulmonary clearance and abnormal cytokine production in response to infection, demonstrating the role of GM-CSF in fending off infection mediated partly by AM innate immune functions (LeVine et al., 1999). Restoring expression of GM-CSF reversed these abnormalities in AM function and reestablished expression of PU.1 (Shibata et al., 2001), a master transcription factor directing macrophage differentiation (Lloberas et al., 1999; Shibata et al., 2001).
Macrophage transcriptome and metabolomic analyses suggest that GM-CSF has pleiotropic effects on macrophage mitochondria that underlie cellular proliferation and differentiation (Wessendarp et al., 2022). Loss of GM-CSF signaling impaired amino acid biosynthesis, glycolysis, and the pentose phosphate pathway suggesting the importance for GM-CSF in facilitating mitochondrial pathways crucial to AM differentiation and proliferation (Wessendarp et al., 2022). These data provide a mitochondrial mechanism and additional understanding of how pulmonary GM-CSF regulates AM population size via STAT5 phosphorylation (Figure 1B) (Suzuki et al., 2014; Wessendarp et al., 2022).
GM-CSF helps to maintain mitochondrial structural integrity, function, and glycolytic activity (Wessendarp et al., 2022). GM-CSF receptor signaling through JAK2 and STAT5 upregulates inflammatory gene expression and results in enhanced glycolysis (Liu et al., 2020). Clearance of fatty acids and phospholipids in surfactant uses mitochondria and requires GM-CSF stimulation and regulation suggesting that GM-CSF signaling may regulate surfactant homeostasis via AM (Figure 1B) (Wessendarp et al., 2022).
5.6 GM-CSF and Alveolar Cell Crosstalk
Expression of GM-CSF by AECII occurs during late gestation after AECII fate specification and coincides with fate initiation of AM in the fetal lung (). Through direct interaction with AECs, GM-CSF also improves epithelial repair processes (), with preclinical data suggesting that GM-CSF may ameliorate lung injury and respiratory failure through limiting early epithelial injury and maintaining AM function (Huffman Reed et al., 1997; Paine et al., 2001; Paine et al., 2003). Recently, new data suggest that AECII-derived GM-CSF is a critical factor modulating AM development and health of mature AM ().
Using single-cell RNA sequencing, 3 main macrophage populations have been identified in the interstitial space and BALF from normal lung samples: FABP4high, FCN1high, and SPP1high (Morse et al., 2019). The FABP4high subset represents the GM-CSF–dependent resident AMs, which are essential for the maintenance of lung homeostasis (Hajivalili et al., 2020). The FCN1high subset is derived from circulating monocytes, while the origin of the SPP1high subset is still unclear (Mari and Crestani, 2019). The FCN1high subset displays a proinflammatory phenotype, and the SPP1high subset is increased in pulmonary fibrosis and is preferentially located in fibrotic areas (Morse et al., 2019; Reyfman et al., 2019). The gene signature and localization of SPP1high macrophages within fibroblast foci suggest they are the primary profibrotic macrophage in pulmonary fibrosis (Mari and Crestani, 2019; Joshi et al., 2020). Significant skewing of the pulmonary macrophage–population distribution has been demonstrated during interstitial pulmonary fibrosis and coronavirus disease 2019 (COVID-19) (Morse et al., 2019; Reyfman et al., 2019; Liao et al., 2020). As diffuse alveolar damage increases, a loss of the FABP4high-, GM-CSF-dependent subset occurs that may give rise to spatially restricted profibrotic niches of monocyte-derived alveolar macrophages that provide signals for fibroblast proliferation (Hajivalili et al., 2020; Joshi et al., 2020; Liao et al., 2020). Therefore, in clinical practice, there is a need to preserve as much of the GM-CSF-dependent resident population as possible to limit the degree of pulmonary fibrosis following injury to the alveolus.
GM-CSF–activated myeloid cells can secrete reactive oxygen species and express cytokines and chemokines which, in turn, attract monocytes, neutrophils, and lymphocytes (Iwasaki et al., 2017; Lang et al., 2020). GM-CSF is critically important to coordinating both innate and adaptive immune responses (Lang et al., 2020). Monocytes, granulocytes, macrophages, and dendritic cells can be modulated directly by GM-CSF via the GM-CSF receptor, thereby enabling autocrine signaling (Shi et al., 2006; Perugini et al., 2010). GM-CSF modulation of T-cell responses is thought to be indirect through the interaction of antigen-presenting cells and T cells (Shi et al., 2006). GM-CSF can enhance the ability of DCs to prime T cells during antigen-specific immune responses. A GM-CSF-producing, specific subset of CD4+ T helper cells has been observed which activates and recruits myeloid cells to amplify the immune response (Lang et al., 2020). proposed that in inflammatory conditions, lymphoid and myeloid cells communicate with each other primarily via GM-CSF (Figure 2).
FIGURE 2
6 GM-CSF and Respiratory Viral Infections
6.1 GM-CSF and Influenza
GM-CSF secreted by AECs can play a key role in protecting against influenza pneumonia (Rosler and Herold, 2016). The pathogen clearance of AMs in GM-CSF−/− mice is impaired, reducing their resistance to influenza, while mice with elevated alveolar GM-CSF show greater AM proliferation and resistance, thus protecting against normally lethal influenza infection. Lung DCs are also critical for mediating GM-CSF−dependent protective effects. After influenza infection, pulmonary DCs activate and expand, and GM-CSF mediates their migration and antigen presentation within the draining mediastinal lymph nodes. This process is associated with improved viral clearance and antigen-specific T cell recruitment. Thus, GM-CSF is critical in mediating epithelial proliferation following lung injury, supporting repair, reestablishing barrier function, and restoring homeostasis.
Halstead et al. (2018) demonstrated GM-CSF overexpression achieved supra-physiologic levels of GM-CSF at the peak of viral replication after influenza A infection and reduced mortality and preserved lung functions in a model of GM-CSF inducible mice (WT C57BL/6 background). Transcriptome data and adoptive transfer studies suggest supraphysiologic GM-CSF in the context of active infection pushed macrophages toward the anti-inflammatory M2 type rather than the proinflammatory M1 type. Reduced interferon signaling in airways was also observed in this study, but more work is needed to elucidate the mechanisms underlying the rescue from ARDS-like illness and GM-CSF–induced plasticity in macrophage phenotype.
6.2 GM-CSF and Coronaviruses
Serum GM-CSF is increased in the infected tissues of patients with conditions similar to late-stage COVID-19, including ARDS (Matute-Bello et al., 1997) and cytokine release syndrome (), as well as the SARS-CoV-2 infection itself (Hue et al., 2020). It has been suggested that SARS-CoV-1 may cause lung fibrosis through the suppression of GM-CSF (Liao et al., 2011). SARS-CoV-2 would likely impact GM-CSF expression similarly. The lung inflammation or damage biomarker Krebs von den Lungen-6 (KL-6) is principally produced by damaged or regenerating AECII (). Recently KL-6 serum concentrations were demonstrated to be significantly higher in patients with severe COVID-19 vs. non-severe COVID-19 and healthy controls, demonstrating potential prognostic value ().
However, lung macrophages in COVID-19 murine models are characterized by the loss of GM-CSF–mediated instruction that drives AM development, resulting in enrichment of lymphocytes, monocytes and neutrophils and depletion of macrophages in the lung (). In COVID-19, instead of lung monocytes developing into AMs with sufficient GM-CSF signal, they develop into proinflammatory CD163+ hemophagocytic macrophages. This parallels findings from murine models demonstrating accumulation of proinflammatory monocytic or macrophagic cell populations that occur in GM-CSF–deficient conditions. Translational studies in mice suggest inhaled GM-CSF may suppress alveolar inflammation by supporting the differentiation of locally recruited monocytes to homeostatic, tissue-resident AMs.
Strategies that target the GM-CSF/GM-CSF–receptor axis have been proposed for patients with COVID-19 with and without ARDS. While GM-CSF may be beneficial for maintaining AM function during the early disease phase, neutralizing GM-CSF may reduce the primary pathology of the cytokine storm and myeloid cell-induced lung destruction in later disease stages (Lang et al., 2020). The role of inhibiting GM-CSF/GM-CSF–receptor interaction in treating patients with COVID-19 is currently under investigation in several clinical studies (; ; ; ; ; ; Temesgen et al., 2020). Notably, anti-GM–CSF monoclonal antibodies used to treat autoimmune disease do not appear to enter the lung, so their usefulness for treating RVI remains to be seen ().
6.3 Rationale for Sargramostim (rhu GM-CSF) for Respiratory Viral Infections
Overexpression of lung-specific GM-CSF in transgenic mice provides notable protection against various seasonal influenza strains and secondary bacterial infection through GM-CSF–dependent expansion of AMs as reviewed in Subramaniam et al. (2015). High levels of airway GM-CSF during active influenza A virus (IAV) infection confers protection from mortality from IAV and prevents the degeneration of multiple lung mechanical properties (Halstead et al., 2018). Administration of inhaled recombinant mouse GM-CSF also protected against secondary bacterial infection during influenza infection. Inhaled recombinant GM-CSF also conferred a significant survival benefit as compared to control (p < 0.05), whereas intraperitoneal injection did not impact survival (Huang et al., 2010; Umstead et al., 2020).
In a small clinical study, inhaled sargramostim (yeast-derived rhu GM-CSF) significantly improved oxygenation (p = 0.0035) without side effects in patients with severe ARDS (Herold et al., 2014), demonstrating GM-CSF is well-tolerated in the alveolar space. Given the beneficial role of inhaled recombinant GM-CSF in reducing mortality in preclinical pneumonia studies, inhaled sargramostim is under investigation to treat patients with COVID-19 (Table 2) (Huang et al., 2010; Huang et al., 2011; ; ; ; ; ).
TABLE 2
| Name | Primary route | NCT number |
|---|---|---|
| Sargramostim use in COVID-19 to recover patient health (SCOPE)a | Inhalation | NCT04707664 |
| Study of sargramostim in patients with COVID-19 (iLeukPulm)a | Inhalation | NCT04411680 |
| A phase II/III study of sargramostim in patients with Coronavirus Disease-2019 | Inhalation | NCT04642950 |
| Sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC) , | Inhalation | NCT04326920 |
| Using GM-CSF as a host directed therapeutic against COVID-19—a phase 2 investigator initiated trial | Intravenous | NCT04400929 |
Sargramostim clinical studies in COVID-19.
Study is supported by the U.S. Department of Defense’s (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), as part of a contract for the advanced development and emergency use of Leukine for COVID-19 treatment (Agreement No. MCDC 2006-0120).
COVID-19, coronavirus disease 2019; GM-CSF, granulocyte-macrophage colony-stimulating factor.
6.4 Clinical Data for Sargramostim
A key feature of sepsis-associated immunosuppression is impaired innate and adaptive immune responses, including monocyte deactivation. A study enrolling patients with severe sepsis (N = 38) demonstrated that subcutaneous sargramostim restored immune function and significantly reduced mechanical ventilation time compared with placebo (148 ± 103 h vs. 207 ± 58 h; p = 0.0037) (Meisel et al., 2009).
Six patients with pneumonia-associated ARDS received inhaled sargramostim (Herold et al., 2014). Sargramostim significantly improved oxygenation and simplified acute physiology scores (SAPS) compared with untreated patients. This is the first evidence that sargramostim may be an effective strategy to stimulate pulmonary host defense and improve oxygenation and clinical outcomes in pneumonia-associated ARDS.
In the multi-center, open-label, randomized, controlled SARPAC trial, 81 non-ventilated hospitalized COVID-19 patients with acute hypoxemic respiratory failure (oxygen saturation below 93% on ≥ 2 L oxygen per minute or a ratio of the partial pressure of oxygen [PaO2] to the fraction of inspired oxygen [FiO2; P/F ratio] below 350 mmHg) the efficacy and safety of 5 days of inhaled sargramostim (125 μg/m2 twice daily) with standard of care (SOC) vs. SOC alone were assessed at day 6 (). More patients in the sargramostim group experienced at least 25% improvement in oxygenation from baseline by day 6 compared with the standard of care group (62.9 vs 39.5%, p = 0.0459). Treatment adverse events, including signs of cytokine storm, were not different between groups. Serum concentrations of pro-inflammatory cytokines in trial patients at day 6 were not increased over baseline levels. Analysis of immune cells suggests inhaled sargramostim impacted B-cell responses and SARS-CoV2–specific CD8 T-cell responses as evidenced by significant increases in circulating switched memory B-cells and CD38+ HLA-DR + effector memory CD8 T-cells after 5 days of sargramostim inhalation vs SOC alone.
7 Discussion and Future Directions
The pleiotropic functional roles of GM-CSF in maintaining homeostasis and host defense against RVI include acting as an immunomodulator, by signaling growth and differentiation of myeloid cells when needed to fight infection, and governing myelopoiesis when macrophage niches within the lung are depleted (; Lang et al., 2020). GM-CSF is essential for driving the maturation and immune functions of AMs including surfactant and pathogen clearance and regulating cytokine responses to lung infection (Trapnell and Whitsett, 2002; Rosler and Herold, 2016). GM-CSF protects the host in the early phase of acute lung infection and during regeneration of the injured lung epithelium (Rosler and Herold, 2016). In the distal airways, GM-CSF promotes pathogen clearance by expanding AM or DCs, or by stimulating their host defense capacity (Rosler and Herold, 2016). GM-CSF supports the development and/or maintenance of CD103+ DCs, serving a crucial role in normal lung health and immune responses (Unkel et al., 2012; Rosler and Herold, 2016). Through direct interaction with AECs, GM-CSF also improves epithelial repair processes, supporting restoration of barrier function and facilitating restored homeostasis ().
Given the multifaceted immunoregulatory roles of GM-CSF in lung health and host defense, careful examination and study should be taken with respect to dose, route, and timing of administration for each therapeutic approach. It is unlikely there will be a one-size-fits-all approach to therapies for patients with RVI, including COVID-19 and influenza (Hall et al., 2020; Lang et al., 2020). With the current preclinical, animal, and small clinical evidence that early administration of inhaled GM-CSF may maintain or restore surfactant levels in ARDS triggered by pulmonary infection (Matute-Bello et al., 2000; Herold et al., 2014), sargramostim may prove beneficial in monocyte-mediated trapping of the inoculum and maintaining adequate alveolar surface tension, thus preventing progression to severe forms of ARDS.
Immunomodulatory therapies that are likely to be successful in patients with COVID-19 are those tailored to the patient’s immunophenotype in real time. Clinical trials of immune modulators for the treatment of COVID-19 should include prospective immunophenotyping and/or subject stratification based on cell counts, immune function assays, cytokine levels, or other markers of inflammation (Hall et al., 2020). Clinical trials are currently underway to evaluate sargramostim in patients with COVID-19 (Table 2) (; ; ; ; ; ). Preclinical studies suggest that sargramostim administration may improve lung function by strengthening the alveolar wall and enhancing viral clearance. Studies of sargramostim administration in SARS-CoV-2 infection, influenza, and other RVIs, and in inhaled fungal or secondary bacterial infections provide further rationale for clinical investigation of sargramostim (Subramaniam et al., 2015).
GM-CSF may provide benefit in the earlier phases of alveolar injury/damage (e.g., influenza infection, SARS-CoV-2 infection, mechanical ventilation, and smoke inhalation) by supporting the tissue-resident AM population and maintaining the best physiologic ratio of resident AMs (Huffman Reed et al., 1997; Paine et al., 2001; Paine et al., 2003; Herold et al., 2014; Rosler and Herold, 2016; Subramaniam et al., 2016). Productive avenues for future research include the possibility of altering the ratios of FCN1+ and SPP1+/FABP4+ AMs to promote pathogen clearance and epithelial repair while limiting exacerbated inflammatory response and pulmonary fibrosis. The issue of appropriate timing for therapeutic modulation of viral pulmonary inflammatory responses is a matter of debate. It may be possible that altering the FCN1+, SPP1+/FABP4+ AM ratio in favor of maintaining a high level of FABP4+ cells may prevent the overwhelming proinflammatory response encountered at the later stages of COVID-19 and other RVIs (Vega et al., 2020).
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Funding
This work was supported by Partner Therapeutics, Inc., Lexington, MA.
Acknowledgments
We thank John Facciponte, from the W2O Group, and Tracey A. Van Kempen, from Centron, for writing services.
Conflict of interest
MG received funds from Partner Therapeutics for other work but none in relation to this manuscript. LL is an employee of and has stock options for Partner Therapeutics, Inc. The authors declare this study received funding from Partner Therapeutics, Inc. The funder had the following involvement with the study: Professional medical writing, graphic artist, and publication fees for this manuscript.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AhmedO. (2019). CAR-T-Cell Neurotoxicity: Hope Is on the Horizon. Blood133 (20), 2114–2116. 10.1182/blood-2019-03-900985
2
Aranda-ValderramaP.KaynarA. M. (2018). The Basic Science and Molecular Mechanisms of Lung Injury and Acute Respiratory Distress Syndrome. Int. Anesthesiol. Clin.56 (1), 1–25. 10.1097/AIA.0000000000000177
3
AspalM.ZemansR. L. (2020). Mechanisms of ATII-To-ATI Cell Differentiation during Lung Regeneration. Int. J. Mol. Sci.21 (9), 3188. 10.3390/ijms21093188
4
BallingerM. N.PaineR.3rdSerezaniC. H.AronoffD. M.ChoiE. S.StandifordT. J.et al (2006). Role of Granulocyte Macrophage Colony-Stimulating Factor during Gram-Negative Lung Infection with Pseudomonas A. Am. J. Respir. Cel. Mol. Biol.34 (6), 766–774. 10.1165/rcmb.2005-0246OC
5
BecherB.TuguesS.GreterM. (2016). GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. Immunity45 (5), 963–973. 10.1016/j.immuni.2016.10.026
6
BeersM. F.MorriseyE. E. (2011). The Three R's of Lung Health and Disease: Repair, Remodeling, and Regeneration. J. Clin. Invest.121 (6), 2065–2073. 10.1172/JCI45961
7
BeharS. M.DivangahiM.RemoldH. G. (2010). Evasion of Innate Immunity by Mycobacterium T: Is Death an Exit Strategy?Nat. Rev. Microbiol.8 (9), 668–674. 10.1038/nrmicro2387
8
BhattacharyaP.BudnickI.SinghM.ThiruppathiM.AlharshawiK.ElshabrawyH.et al (2015). Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. J. Interferon Cytokine Res.35 (8), 585–599. 10.1089/jir.2014.0149
9
BissonnetteE. Y.Lauzon-JosetJ. F.DebleyJ. S.ZieglerS. F. (2020). Cross-Talk between Alveolar Macrophages and Lung Epithelial Cells Is Essential to Maintain Lung Homeostasis. Front. Immunol.11, 583042. 10.3389/fimmu.2020.583042
10
Boada-RomeroE.MartinezJ.HeckmannB. L.GreenD. R. (2020). The Clearance of Dead Cells by Efferocytosis. Nat. Rev. Mol. Cel. Biol.21 (7), 398–414. 10.1038/s41580-020-0232-1
11
BonfieldT. L.FarverC. F.BarnaB. P.MalurA.AbrahamS.RaychaudhuriB.et al (2003). Peroxisome Proliferator-Activated Receptor-Gamma Is Deficient in Alveolar Macrophages from Patients with Alveolar Proteinosis. Am. J. Respir. Cel. Mol. Biol.29 (6), 677–682. 10.1165/rcmb.2003-0148OC
12
BosteelsC.Van DammeK.De LeeuwE.DeclercqJ.MaesB.BosteelsV.et al (2021). Early Treatment with Inhaled GM-CSF Improves Oxygenation and Anti-viral Immunity in COVID-19 Induced Lung Injury - a Randomized Clinical Trial. Res. Square. [preprint]. 10.21203/rs.3.rs-959220/v1
13
BurgJ.Krump-KonvalinkovaV.BittingerF.KirkpatrickC. J. (2002). GM-CSF Expression by Human Lung Microvascular Endothelial Cells: In Vitro and In Vivo Findings. Am. J. Physiol. Lung Cel. Mol. Physiol.283 (2), L460–L467. 10.1152/ajplung.00249.2001
14
BurgessA. W.CamakarisJ.MetcalfD. (1977). Purification and Properties of Colony-Stimulating Factor from Mouse Lung-Conditioned Medium. J. Biol. Chem.252 (6), 1998–2003. 10.1016/s0021-9258(18)71855-3
15
CakarovaL.MarshL. M.WilhelmJ.MayerK.GrimmingerF.SeegerW.et al (2009). Macrophage Tumor Necrosis Factor-Alpha Induces Epithelial Expression of Granulocyte-Macrophage Colony-Stimulating Factor: Impact on Alveolar Epithelial Repair. Am. J. Respir. Crit. Care Med.180 (6), 521–532. 10.1164/rccm.200812-1837OC
16
CampbellJ.NysJ.EghobamienL.CohenE. S.RobinsonM. J.SleemanM. A. (2016). Pulmonary Pharmacodynamics of an Anti-GM-CSFRα Antibody Enables Therapeutic Dosing that Limits Exposure in the Lung. MAbs8 (7), 1398–1406. 10.1080/19420862.2016.1215790
17
ChoudharyG. S.YaoX.WangJ.PengB.BaderR. A.RenD. (2015). Human Granulocyte Macrophage colony-stimulating Factor Enhances Antibiotic Susceptibility of Pseudomonas A Persister Cells. Sci. Rep.5, 17315. 10.1038/srep17315
18
ClinicalTrials.Gov (2020c). A Phase II/III Study of Sargramostim in Patients with Coronavirus Disease-2019 (COVID-19). [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT04642950 (Accessed January 15, 2021).
19
ClinicalTrials.Gov (2020h). A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects with Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE). [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT04351243 (Accessed January 15, 2021).
20
ClinicalTrials.Gov (2020a). Investigating Otilimab in Patients with Severe Pulmonary COVID-19 Related Disease (OSCAR). [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT04376684 (Accessed January 15, 2021).
21
ClinicalTrials.Gov (2020b). Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients with COVID-19. [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT04351152 (Accessed January 15, 2021).
22
ClinicalTrials.Gov (2020d). Sargramostim in Patients with Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC). [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT04326920 (Accessed January 15, 2021).
23
ClinicalTrials.Gov (2021). Sargramostim Use in COVID-19 to Recover Patient Health (SCOPE). [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT04707664 (Accessed January 15, 2021).
24
ClinicalTrials.Gov (2020e). Study of Mavrilimumab (KPL-301) in Participants Hospitalized with Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-Inflammation. [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT04447469 (Accessed January 15, 2021).
25
ClinicalTrials.Gov (2020f). Study of Sargramostim in Patients with COVID-19 (iLeukPulm). [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT04411680 (Accessed January 15, 2021).
26
ClinicalTrials.Gov (2020g). Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects with Severe Coronavirus Disease 2019 (COVID-19). [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT04341116 (Accessed January 15, 2021).
27
ClinicalTrials.Gov (2020i). Using GM-CSF as a Host Directed Therapeutic against COVID-19 - a Phase 2 Investigator Initiated Trial. [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT04400929 (Accessed January 15, 2021).
28
CostaE. L.AmatoM. B. (2013). The New Definition for Acute Lung Injury and Acute Respiratory Distress Syndrome: Is There Room for Improvement?Curr. Opin. Crit. Care.19 (1), 16–23. 10.1097/MCC.0b013e32835c50b1
29
CusumanoJ. A.DupperA. C.MalikY.GavioliE. M.BangaJ.Berbel CabanA.et al (2020). Staphylococcus Aureus Bacteremia in Patients Infected with COVID-19: A Case Series. Open Forum Infect. Dis.7 (11), ofaa518. 10.1093/ofid/ofaa518
30
d'AlessandroM.CameliP.RefiniR. M.BergantiniL.AlonziV.LanzaroneN.et al (2020). Serum KL-6 Concentrations as a Novel Biomarker of Severe COVID-19. J. Med. Virol.92, 2216–2220. 10.1002/jmv.26087
31
DamianiG.McCormickT. S.LealL. O.GhannoumM. A. (2020). Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor Expressed in Yeast (Sargramostim): A Potential Ally to Combat Serious Infections. Clin. Immunol.210, 108292. 10.1016/j.clim.2019.108292
32
De LucaG.CavalliG.CampochiaroC.Della-TorreE.AngelilloP.TomelleriA.et al (2020). GM-CSF Blockade with Mavrilimumab in Severe COVID-19 Pneumonia and Systemic Hyperinflammation: A Single-Centre, Prospective Cohort Study. Lancet Rheumatol.2 (8), e465–e473. 10.1016/S2665-9913(20)30170-3
33
DeepeG. S.Jr.GibbonsR.WoodwardE. (1999). Neutralization of Endogenous Granulocyte-Macrophage colony-stimulating Factor Subverts the Protective Immune Response to Histoplasma Capsulatum. J. Immunol.163 (9), 4985–4993.
34
DelpinoM. V.QuarleriJ. (2020). SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis. Front. Cel. Infect. Microbiol.10, 340. 10.3389/fcimb.2020.00340
35
DuhenT.CampbellD. J. (2014). IL-1β Promotes the Differentiation of Polyfunctional Human CCR6+CXCR3+ Th1/17 Cells that Are Specific for Pathogenic and Commensal Microbes. J. Immunol.193 (1), 120–129. 10.4049/jimmunol.1302734
36
EvrenE.RingqvistE.WillingerT. (2020). Origin and Ontogeny of Lung Macrophages: from Mice to Humans. Immunology160 (2), 126–138. 10.1111/imm.13154
37
FadokV. A.BrattonD. L.KonowalA.FreedP. W.WestcottJ. Y.HensonP. M. (1998). Macrophages that Have Ingested Apoptotic Cells In Vitro Inhibit Proinflammatory Cytokine Production through Autocrine/paracrine Mechanisms Involving TGF-Beta, PGE2, and PAF. J. Clin. Invest.101 (4), 890–898. 10.1172/JCI1112
38
FehrenbachH. (2001). Alveolar Epithelial Type II Cell: Defender of the Alveolus Revisited. Respir. Res.2 (1), 33–46. 10.1186/rr36
39
FengY.LingY.BaiT.XieY.HuangJ.LiJ.et al (2020). COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am. J. Respir. Crit. Care Med.201 (11), 1380–1388. 10.1164/rccm.202002-0445OC
40
FitzgeraldS. M.ChiD. S.HallH. K.ReynoldsS. A.AramideO.LeeS. A.et al (2003). GM-CSF Induction in Human Lung Fibroblasts by IL-1beta, TNF-Alpha, and Macrophage Contact. J. Interferon Cytokine Res.23 (2), 57–65. 10.1089/107999003321455453
41
GonzálezA. E.LayM. K.JaraE. L.EspinozaJ. A.GómezR. S.SotoJ.et al (2017). Aberrant T Cell Immunity Triggered by Human Respiratory Syncytial Virus and Human Metapneumovirus Infection. Virulence8 (6), 685–704. 10.1080/21505594.2016.1265725
42
Gonzalez-JuarreroM.HattleJ. M.IzzoA.Junqueira-KipnisA. P.ShimT. S.TrapnellB. C.et al (2005). Disruption of Granulocyte Macrophage-Colony Stimulating Factor Production in the Lungs Severely Affects the Ability of Mice to Control Mycobacterium T Infection. J. Leukoc. Biol.77 (6), 914–922. 10.1189/jlb.1204723
43
GoyalS.Castrillón-BetancurJ. C.KlaileE.SlevogtH. (2018). The Interaction of Human Pathogenic Fungi with C-Type Lectin Receptors. Front. Immunol.9, 1261. 10.3389/fimmu.2018.01261
44
GschwendJ.ShermanS.RidderF.FengX.LiangH.-E.LocksleyR. M.et al (2021). Alveolar Macrophages Rely on GM-CSF from Alveolar Epithelial Type 2 Cells before and after Birth. J. Exp. Med.218 (10), e20210745. 10.1084/jem.20210745
45
Guerrero-PlataA.CasolaA.GarofaloR. P. (2005). Human Metapneumovirus Induces a Profile of Lung Cytokines Distinct from that of Respiratory Syncytial Virus. J. Virol.79 (23), 14992–14997. 10.1128/JVI.79.23.14992-14997.2005
46
Guillamat-PratsR.PuigF.Camprubí-RimblasM.HerreroR.Serrano-MollarA.GómezM. N.et al (2018). Intratracheal Instillation of Alveolar Type II Cells Enhances Recovery from Acute Lung Injury in Rats. J. Heart Lung Transpl.37 (6), 782–791. 10.1016/j.healun.2017.10.025
47
GuilliamsM.De KleerI.HenriS.PostS.VanhoutteL.De PrijckS.et al (2013). Alveolar Macrophages Develop from Fetal Monocytes that Differentiate into Long-Lived Cells in the First Week of Life via GM-CSF. J. Exp. Med.210 (10), 1977–1992. 10.1084/jem.20131199
48
GuilliamsM.ThierryG. R.BonnardelJ.BajenoffM. (2020). Establishment and Maintenance of the Macrophage Niche. Immunity52 (3), 434–451. 10.1016/j.immuni.2020.02.015
49
GuillotL.NathanN.TabaryO.ThouveninG.Le RouzicP.CorvolH.et al (2013). Alveolar Epithelial Cells: Master Regulators of Lung Homeostasis. Int. J. Biochem. Cel. Biol.45 (11), 2568–2573. 10.1016/j.biocel.2013.08.009
50
HajivaliliM.HosseiniM.Haji-FatahalihaM. (2020). Gaining Insights on Immune Responses to the Novel Coronavirus, COVID-19 and Therapeutic Challenges. Life Sci.257, 118058. 10.1016/j.lfs.2020.118058
51
HallM. W.JoshiI.LealL.OoiE. E. (2020). Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention. Clin. Infect. Dis, ciaa904. 10.1093/cid/ciaa904
52
HalsteadE. S.UmsteadT. M.DaviesM. L.KawasawaY. I.SilveyraP.HowyrlakJ.et al (2018). GM-CSF Overexpression after Influenza A Virus Infection Prevents Mortality and Moderates M1-like Airway Monocyte/macrophage Polarization. Respir. Res.19 (1), 3. 10.1186/s12931-017-0708-5
53
HamiltonJ. A. (2015). GM-CSF as a Target in Inflammatory/autoimmune Disease: Current Evidence and Future Therapeutic Potential. Expert Rev. Clin. Immunol.11 (4), 457–465. 10.1586/1744666X.2015.1024110
54
HamiltonJ. A. (2019). GM-CSF-Dependent Inflammatory Pathways. Front. Immunol.10, 2055. 10.3389/fimmu.2019.02055
55
HarrisR. J.PettittA. R.SchmutzC.SherringtonP. D.ZuzelM.CawleyJ. C.et al (2000). Granulocyte-Macrophage Colony-Stimulating Factor as an Autocrine Survival Factor for Mature Normal and Malignant B Lymphocytes. J. Immunol.164 (7), 3887–3893. 10.4049/jimmunol.164.7.3887
56
HaschekW. M.WitschiH. (1979). Pulmonary Fibrosis-A Possible Mechanism. Toxicol. Appl. Pharmacol.51 (3), 475–487. 10.1016/0041-008x(79)90372-7
57
HeroldS.HoegnerK.VadászI.GesslerT.WilhelmJ.MayerK.et al (2014). Inhaled Granulocyte/Macrophage Colony-Stimulating Factor as Treatment of Pneumonia-Associated Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care Med.189 (5), 609–611. 10.1164/rccm.201311-2041LE
58
HerzogE. L.BrodyA. R.ColbyT. V.MasonR.WilliamsM. C. (2008). Knowns and Unknowns of the Alveolus. Proc. Am. Thorac. Soc.5 (7), 778–782. 10.1513/pats.200803-028HR
59
HigginsG.Fustero TorreC.TyrrellJ.McNallyP.HarveyB. J.UrbachV. (2016). Lipoxin A4 Prevents Tight junction Disruption and Delays the Colonization of Cystic Fibrosis Bronchial Epithelial Cells by Pseudomonas A. Am. J. Physiol. Lung Cel. Mol. Physiol.310 (11), L1053–L1061. 10.1152/ajplung.00368.2015
60
HoffmannM.Kleine-WeberH.SchroederS.KrügerN.HerrlerT.ErichsenS.et al (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell181 (2), 271–280. e278. 10.1016/j.cell.2020.02.052
61
HuangC.WangY.LiX.RenL.ZhaoJ.HuY.et al (2020). Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet395 (10223), 497–506. 10.1016/S0140-6736(20)30183-5
62
HuangF. F.BarnesP. F.FengY.DonisR.ChroneosZ. C.IdellS.et al (2011). GM-CSF in the Lung Protects against Lethal Influenza Infection. Am. J. Respir. Crit. Care Med.184 (2), 259–268. 10.1164/rccm.201012-2036OC
63
HuangH.LiH.ZhouP.JuD. (2010). Protective Effects of Recombinant Human Granulocyte Macrophage Colony Stimulating Factor on H1N1 Influenza Virus-Induced Pneumonia in Mice. Cytokine51 (2), 151–157. 10.1016/j.cyto.2010.04.001
64
HueS.Beldi-FerchiouA.BendibI.SurenaudM.FouratiS.FrapardT.et al (2020). Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care Med.202 (11), 1509–1519. 10.1164/rccm.202005-1885OC
65
HuffmanJ. A.HullW. M.DranoffG.MulliganR. C.WhitsettJ. A. (1996). Pulmonary Epithelial Cell Expression of GM-CSF Corrects the Alveolar Proteinosis in GM-CSF-Deficient Mice. J. Clin. Invest.97 (3), 649–655. 10.1172/JCI118461
66
Huffman ReedJ. A.RiceW. R.ZsengellérZ. K.WertS. E.DranoffG.WhitsettJ. A. (1997). GM-CSF Enhances Lung Growth and Causes Alveolar Type II Epithelial Cell Hyperplasia in Transgenic Mice. Am. J. Physiol.273 (4), L715–L725. 10.1152/ajplung.1997.273.4.L715
67
IshiiH.HayashiS.HoggJ. C.FujiiT.GotoY.SakamotoN.et al (2005). Alveolar Macrophage-Epithelial Cell Interaction Following Exposure to Atmospheric Particles Induces the Release of Mediators Involved in Monocyte Mobilization and Recruitment. Respir. Res.6, 87. 10.1186/1465-9921-6-87
68
IwasakiA.FoxmanE. F.MolonyR. D. (2017). Early Local Immune Defences in the Respiratory Tract. Nat. Rev. Immunol.17 (1), 7–20. 10.1038/nri.2016.117
69
JanssenW. J.BarthelL.MuldrowA.Oberley-DeeganR. E.KearnsM. T.JakubzickC.et al (2011). Fas Determines Differential Fates of Resident and Recruited Macrophages during Resolution of Acute Lung Injury. Am. J. Respir. Crit. Care Med.184 (5), 547–560. 10.1164/rccm.201011-1891OC
70
JohnsonB. V.BertA. G.RyanG. R.CondinaA.CockerillP. N. (2004). Granulocyte-Macrophage Colony-Stimulating Factor Enhancer Activation Requires Cooperation between NFAT and AP-1 Elements and Is Associated with Extensive Nucleosome Reorganization. Mol. Cel. Biol.24 (18), 7914–7930. 10.1128/mcb.24.18.7914-7930.2004
71
JoshiN.WatanabeS.VermaR.JablonskiR. P.ChenC. I.ChereshP.et al (2020). A Spatially Restricted Fibrotic Niche in Pulmonary Fibrosis Is Sustained by M-CSF/M-CSFR Signalling in Monocyte-Derived Alveolar Macrophages. Eur. Respir. J.55 (1), 1900646. 10.1183/13993003.00646-2019
72
KimK. K.DotsonM. R.AgarwalM.YangJ.BradleyP. B.SubbotinaN.et al (2018). Efferocytosis of Apoptotic Alveolar Epithelial Cells Is Sufficient to Initiate Lung Fibrosis. Cell Death Dis.9 (11), 1056. 10.1038/s41419-018-1074-z
73
KnutsenA. P.BelloneC.KauffmanH. (2002). Immunopathogenesis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. J. Cyst Fibros1 (2), 76–89. 10.1016/S1569-1993(02)00033-4
74
KogaY.HisadaT.IshizukaT.UtsugiM.OnoA.YatomiM.et al (2016). CREB Regulates TNF-α-Induced GM-CSF Secretion via P38 MAPK in Human Lung Fibroblasts. Allergol. Int.65 (4), 406–413. 10.1016/j.alit.2016.03.006
75
KomuczkiJ.TuzlakS.FriebelE.HartwigT.SpathS.RosenstielP.et al (2019). Fate-Mapping of GM-CSF Expression Identifies a Discrete Subset of Inflammation-Driving T Helper Cells Regulated by Cytokines IL-23 and IL-1β. Immunity50 (5), 1289–1304. 10.1016/j.immuni.2019.04.006
76
KoushaM.TadiR.SoubaniA. O. (2011). Pulmonary Aspergillosis: A Clinical Review. Eur. Respir. Rev.20 (121), 156–174. 10.1183/09059180.00001011
77
LambrechtB. N. (2017). TGF-β Gives an Air of Exclusivity to Alveolar Macrophages. Immunity47 (5), 807–809. 10.1016/j.immuni.2017.11.005
78
LangF. M.LeeK. M.TeijaroJ. R.BecherB.HamiltonJ. A. (2020). GM-CSF-Based Treatments in COVID-19: Reconciling Opposing Therapeutic Approaches. Nat. Rev. Immunol.20 (8), 507–514. 10.1038/s41577-020-0357-7
79
LavinY.MorthaA.RahmanA.MeradM. (2015). Regulation of Macrophage Development and Function in Peripheral Tissues. Nat. Rev. Immunol.15 (12), 731–744. 10.1038/nri3920
80
LeVineA. M.ReedJ. A.KurakK. E.CiancioloE.WhitsettJ. A. (1999). GM-CSF-deficient Mice Are Susceptible to Pulmonary Group B Streptococcal Infection. J. Clin. Invest.103 (4), 563–569. 10.1172/JCI5212
81
LiX.MaX. (2020). Acute Respiratory Failure in COVID-19: Is it "Typical" ARDS?Crit. Care24 (1), 198. 10.1186/s13054-020-02911-9
82
LiY.WangY.LiuX. (2012). The Role of Airway Epithelial Cells in Response to Mycobacteria Infection. Clin. Dev. Immunol.2012, 791392. 10.1155/2012/791392
83
LiaoH. H.WangY. C.ChenM. C.TsaiH. Y.LinJ.ChenS. T.et al (2011). Down-Regulation of Granulocyte-Macrophage Colony-Stimulating Factor by 3C-like Proteinase in Transfected A549 Human Lung Carcinoma Cells. BMC Immunol.12, 16. 10.1186/1471-2172-12-16
84
LiaoM.LiuY.YuanJ.WenY.XuG.ZhaoJ.et al (2020). Single-Cell Landscape of Bronchoalveolar Immune Cells in Patients with COVID-19. Nat. Med.26 (6), 842–844. 10.1038/s41591-020-0901-9
85
LiuX.BoyerM. A.HolmgrenA. M.ShinS. (2020). Legionella-infected Macrophages Engage the Alveolar Epithelium to Metabolically Reprogram Myeloid Cells and Promote Antibacterial Inflammation. Cell Host & Microbe28, 683–698. 10.1016/j.chom.2020.07.019
86
LloberasJ.SolerC.CeladaA. (1999). The Key Role of PU.1/SPI-1 in B Cells, Myeloid Cells and Macrophages. Immunol. Today20 (4), 184–189. 10.1016/s0167-5699(99)01442-5
87
MaertzdorfJ.TönniesM.LozzaL.Schommer-LeitnerS.MollenkopfH.BauerT. T.et al (2018). Mycobacterium T Invasion of the Human Lung: First Contact. Front. Immunol.9, 1346. 10.3389/fimmu.2018.01346
88
MariB.CrestaniB. (2019). Dysregulated Balance of Lung Macrophage Populations in Idiopathic Pulmonary Fibrosis Revealed by Single-Cell RNA Seq: an Unstable “Ménage-À-Trois”. Eur. Respir. J.54 (2), 1901229. 10.1183/13993003.01229-2019
89
MarrK. A.PlattA.TornheimJ. A.ZhangS. X.DattaK.CardozoC.et al (2021). Aspergillosis Complicating Severe Coronavirus Disease. Emerg. Infect. Dis.27 (1), 18–25. 10.3201/eid2701.202896
90
MartinC. J.PetersK. N.BeharS. M. (2014). Macrophages Clean up: Efferocytosis and Microbial Control. Curr. Opin. Microbiol.17, 17–23. 10.1016/j.mib.2013.10.007
91
MasonR. J. (2006). Biology of Alveolar Type II Cells. Respirology11, S12–S15. 10.1111/j.1440-1843.2006.00800.x
92
MasonR. J. (2020). Thoughts on the Alveolar Phase of COVID-19. Am. J. Physiol. Lung Cel. Mol. Physiol.319 (1), L115–L120. 10.1152/ajplung.00126.2020
93
Matute-BelloG.LilesW. C.RadellaF.2ndSteinbergK. P.RuzinskiJ. T.HudsonL. D.et al (2000). Modulation of Neutrophil Apoptosis by Granulocyte colony-stimulating Factor and Granulocyte/Macrophage Colony-Stimulating Factor during the Course of Acute Respiratory Distress Syndrome. Crit. Care Med.28 (1), 1–7. 10.1097/00003246-200001000-00001
94
Matute-BelloG.LilesW. C.RadellaF.2ndSteinbergK. P.RuzinskiJ. T.JonasM.et al (1997). Neutrophil Apoptosis in the Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care Med.156 (6), 1969–1977. 10.1164/ajrccm.156.6.96-12081
95
McDonaldP. P.FadokV. A.BrattonD.HensonP. M. (1999). Transcriptional and Translational Regulation of Inflammatory Mediator Production by Endogenous TGF-Beta in Macrophages that Have Ingested Apoptotic Cells. J. Immunol.163 (11), 6164–6172.
96
MeiselC.SchefoldJ. C.PschowskiR.BaumannT.HetzgerK.GregorJ.et al (2009). Granulocyte-Macrophage Colony-Stimulating Factor to Reverse Sepsis-Associated Immunosuppression: a Double-Blind, Randomized, Placebo-Controlled Multicenter Trial. Am. J. Respir. Crit. Care Med.180 (7), 640–648. 10.1164/rccm.200903-0363OC
97
MetcalfD. (1986). The Molecular Biology and Functions of the Granulocyte-Macrophage Colony-Stimulating Factors. Blood67 (2), 257–267. 10.1182/blood.v67.2.257.bloodjournal672257
98
Mir-KasimovM.SturrockA.McManusM.PaineR.3rd (2012). Effect of Alveolar Epithelial Cell Plasticity on the Regulation of GM-CSF Expression. Am. J. Physiol. Lung Cel. Mol. Physiol.302 (6), L504–L511. 10.1152/ajplung.00303.2010
99
MisharinA. V.Morales-NebredaL.ReyfmanP. A.CudaC. M.WalterJ. M.McQuattie-PimentelA. C.et al (2017). Monocyte-Derived Alveolar Macrophages Drive Lung Fibrosis and Persist in the Lung Over the Life Span. J. Exp. Med.214 (8), 2387–2404. 10.1084/jem.20162152
100
MishraA.SinghV. K.ActorJ. K.HunterR. L.JagannathC.SubbianS.et al (2020). GM-CSF Dependent Differential Control of Mycobacterium T Infection in Human and Mouse Macrophages: Is Macrophage Source of GM-CSF Critical to Tuberculosis Immunity?Front. Immunol.11, 1599. 10.3389/fimmu.2020.01599
101
Morales-NebredaL.MisharinA. V.PerlmanH.BudingerG. R. (2015). The Heterogeneity of Lung Macrophages in the Susceptibility to Disease. Eur. Respir. Rev.24 (137), 505–509. 10.1183/16000617.0031-2015
102
MorseC.TabibT.SembratJ.BuschurK. L.BittarH. T.ValenziE.et al (2019). Proliferating SPP1/MERTK-Expressing Macrophages in Idiopathic Pulmonary Fibrosis. Eur. Respir. J.54 (2), 1802441. 10.1183/13993003.02441-2018
103
MulugetaS.NurekiS.BeersM. F. (2015). Lost after Translation: Insights from Pulmonary Surfactant for Understanding the Role of Alveolar Epithelial Dysfunction and Cellular Quality Control in Fibrotic Lung Disease. Am. J. Physiol. Lung Cel. Mol. Physiol.309 (6), L507–L525. 10.1152/ajplung.00139.2015
104
NewtonA. H.CardaniA.BracialeT. J. (2016). The Host Immune Response in Respiratory Virus Infection: Balancing Virus Clearance and Immunopathology. Semin. Immunopathol.38 (4), 471–482. 10.1007/s00281-016-0558-0
105
OhkouchiS.AkasakaK.IchiwataT.HisataS.IijimaH.TakadaT.et al (2017). Sequential Granulocyte-Macrophage Colony-Stimulating Factor Inhalation after Whole-Lung Lavage for Pulmonary Alveolar Proteinosis. A Report of Five Intractable Cases. Ann. Am. Thorac. Soc.14 (8), 1298–1304. 10.1513/AnnalsATS.201611-892BC
106
Ortega-GómezA.PerrettiM.SoehnleinO. (2013). Resolution of Inflammation: An Integrated View. EMBO Mol. Med.5 (5), 661–674. 10.1002/emmm.201202382
107
PaineR.3rdMorrisS. B.JinH.WilcoxenS. E.PhareS. M.MooreB. B.et al (2001). Impaired Functional Activity of Alveolar Macrophages from GM-CSF-Deficient Mice. Am. J. Physiol. Lung Cel. Mol. Physiol.281 (5), L1210–L1218. 10.1152/ajplung.2001.281.5.L1210
108
PaineR.3rdWilcoxenS. E.MorrisS. B.SartoriC.BaleeiroC. E.MatthayM. A.et al (2003). Transgenic Overexpression of Granulocyte Macrophage-Colony Stimulating Factor in the Lung Prevents Hyperoxic Lung Injury. Am. J. Pathol.163 (6), 2397–2406. 10.1016/S0002-9440(10)63594-8
109
PelaiaC.TinelloC.VatrellaA.De SarroG.PelaiaG. (2020). Lung under Attack by COVID-19-Induced Cytokine Storm: Pathogenic Mechanisms and Therapeutic Implications. Ther. Adv. Respir. Dis.14, 1753466620933508. 10.1177/1753466620933508
110
PeruginiM.BrownA. L.SalernoD. G.BookerG. W.StojkoskiC.HercusT. R.et al (2010). Alternative Modes of GM-CSF Receptor Activation Revealed Using Activated Mutants of the Common Beta-Subunit. Blood115 (16), 3346–3353. 10.1182/blood-2009-08-235846
111
PietersJ. (2008). Mycobacterium T and the Macrophage: Maintaining a Balance. Cell Host Microbe3 (6), 399–407. 10.1016/j.chom.2008.05.006
112
PisonU.BrandM.JokaT.ObertackeU.BruchJ. (1988). Distribution and Function of Alveolar Cells in Multiply Injured Patients with Trauma-Induced ARDS. Intensive Care Med.14 (6), 602–609. 10.1007/BF00256763
113
PolidoroR. B.HaganR. S.de Santis SantiagoR.SchmidtN. W. (2020). Overview: Systemic Inflammatory Response Derived from Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. Front. Immunol.11, 1626. 10.3389/fimmu.2020.01626
114
PrompetcharaE.KetloyC.PalagaT. (2020). Immune Responses in COVID-19 and Potential Vaccines: Lessons Learned from SARS and MERS Epidemic. Asian Pac. J. Allergy Immunol.38 (1), 1–9. 10.12932/AP-200220-0772
115
QuillH.GaurA.PhippsR. P. (1989). Prostaglandin E2-Dependent Induction of Granulocyte-Macrophage Colony-Stimulating Factor Secretion by Cloned Murine Helper T Cells. J. Immunol.142 (3), 813–818.
116
ReyfmanP. A.WalterJ. M.JoshiN.AnekallaK. R.McQuattie-PimentelA. C.ChiuS.et al (2019). Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med.199 (12), 1517–1536. 10.1164/rccm.201712-2410OC
117
RöslerB.HeroldS. (2016). Lung Epithelial GM-CSF Improves Host Defense Function and Epithelial Repair in Influenza Virus Pneumonia-A New Therapeutic Strategy?Mol. Cel. Pediatr.3 (1), 29. 10.1186/s40348-016-0055-5
118
RubinsJ. B. (2003). Alveolar Macrophages: Wielding the Double-Edged Sword of Inflammation. Am. J. Respir. Crit. Care Med.167 (2), 103–104. 10.1164/rccm.2210007
119
SadikotR. T.BlackwellT. S.ChristmanJ. W.PrinceA. S. (2005). Pathogen-host Interactions in Pseudomonas aeruginosa Pneumonia. Am. J. Respir. Crit. Care Med.171 (11), 1209–1223. 10.1164/rccm.200408-1044SO
120
ShangC.AttemaJ.CakourosD.CockerillP. N.ShannonM. F. (1999). Nuclear Factor of Activated T Cells Contributes to the Function of the CD28 Response Region of the Granulocyte Macrophage-Colony Stimulating Factor Promoter. Int. Immunol.11 (12), 1945–1956. 10.1093/intimm/11.12.1945
121
ShiY.LiuC. H.RobertsA. I.DasJ.XuG.RenG.et al (2006). Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and T-Cell Responses: What We Do and Don't Know. Cell Res.16 (2), 126–133. 10.1038/sj.cr.7310017
122
ShibataY.BerclazP. Y.ChroneosZ. C.YoshidaM.WhitsettJ. A.TrapnellB. C. (2001). GM-CSF Regulates Alveolar Macrophage Differentiation and Innate Immunity in the Lung through PU.1. Immunity15 (4), 557–567. 10.1016/s1074-7613(01)00218-7
123
ShiomiA.UsuiT. (2015). Pivotal Roles of GM-CSF in Autoimmunity and Inflammation. Mediators Inflamm.2015, 568543. 10.1155/2015/568543
124
ShortK. R.KasperJ.van der AaS.AndewegA. C.Zaaraoui-BoutaharF.GoeijenbierM.et al (2016). Influenza Virus Damages the Alveolar Barrier by Disrupting Epithelial Cell Tight Junctions. Eur. Respir. J.47 (3), 954–966. 10.1183/13993003.01282-2015
125
SinghS.BarrH.LiuY. C.RobinsA.HeebS.WilliamsP.et al (2015). Granulocyte-Macrophage colony Stimulatory Factor Enhances the Pro-inflammatory Response of Interferon-γ-Treated Macrophages to Pseudomonas A Infection. PLoS One10 (2), e0117447. 10.1371/journal.pone.0117447
126
SmithA. M.McCullersJ. A. (2014). Secondary Bacterial Infections in Influenza Virus Infection Pathogenesis. Curr. Top. Microbiol. Immunol.385, 327–356. 10.1007/82_2014_394
127
SpagnoloP.BalestroE.AlibertiS.CocconcelliE.BiondiniD.CasaG. D.et al (2020). Pulmonary Fibrosis Secondary to COVID-19: a Call to Arms?Lancet Respir. Med.8 (8), 750–752. 10.1016/S2213-2600(20)30222-8
128
SteinbachW. J.StevensD. A.DenningD. W.MossR. B. (2003). Advances against Aspergillosis. Clin. Infect. Dis.37 (Suppl. 3), S155–S156. 10.1086/376522
129
SturrockA.SeedahmedE.Mir-KasimovM.BoltaxJ.McManusM. L.PaineR.3rd (2012). GM-CSF Provides Autocrine protection for Murine Alveolar Epithelial Cells from Oxidant-Induced Mitochondrial Injury. Am. J. Physiol. Lung Cel. Mol. Physiol.302 (3), L343–L351. 10.1152/ajplung.00276.2011
130
SubramaniamR.HillberryZ.ChenH.FengY.FletcherK.NeuenschwanderP.et al (2015). Delivery of GM-CSF to Protect Against Influenza Pneumonia. PLoS One10 (4), e0124593. 10.1371/journal.pone.0124593
131
SubramaniamR.MukherjeeS.ChenH.KeshavaS.NeuenschwanderP.ShamsH. (2016). Restoring Cigarette Smoke-Induced Impairment of Efferocytosis in Alveolar Macrophages. Mucosal Immunol.9 (4), 873–883. 10.1038/mi.2015.120
132
Subramanian VigneshK.Landero FigueroaJ. A.PorolloA.CarusoJ. A.DeepeG. S.Jr. (2013). Granulocyte Macrophage-Colony Stimulating Factor Induced Zn Sequestration Enhances Macrophage Superoxide and Limits Intracellular Pathogen Survival. Immunity39 (4), 697–710. 10.1016/j.immuni.2013.09.006
133
SuzukiT.ArumugamP.SakagamiT.LachmannN.ChalkC.SalleseA.et al (2014). Pulmonary Macrophage Transplantation Therapy. Nature514 (7523), 450–454. 10.1038/nature13807
134
TanS. Y.KrasnowM. A. (2016). Developmental Origin of Lung Macrophage Diversity. Development143 (8), 1318–1327. 10.1242/dev.129122
135
TaoF.KobzikL. (2002). Lung Macrophage-Epithelial Cell Interactions Amplify Particle-Mediated Cytokine Release. Am. J. Respir. Cel. Mol. Biol.26 (4), 499–505. 10.1165/ajrcmb.26.4.4749
136
TasherD.SteinM.SimõesE. A.ShohatT.BrombergM.SomekhE. (2011). Invasive Bacterial Infections in Relation to Influenza Outbreaks, 2006-2010. Clin. Infect. Dis.53 (12), 1199–1207. 10.1093/cid/cir726
137
TazawaR.TrapnellB. C.InoueY.AraiT.TakadaT.NasuharaY.et al (2010). Inhaled Granulocyte/macrophage-colony Stimulating Factor as Therapy for Pulmonary Alveolar Proteinosis. Am. J. Respir. Crit. Care Med.181 (12), 1345–1354. 10.1164/rccm.200906-0978OC
138
TemesgenZ.AssiM.ShwetaF. N. U.VergidisP.RizzaS. A.BauerP. R.et al (2020). GM-CSF Neutralization with Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin. Proc.95 (11), 2382–2394. 10.1016/j.mayocp.2020.08.038
139
TrapnellB. C.WhitsettJ. A. (2002). GM-CSF Regulates Pulmonary Surfactant Homeostasis and Alveolar Macrophage-Mediated Innate Host Defense. Annu. Rev. Physiol.64, 775–802. 10.1146/annurev.physiol.64.090601.113847
140
UchidaT.ShirasawaM.WareL. B.KojimaK.HataY.MakitaK.et al (2006). Receptor for Advanced Glycation End-Products Is a Marker of Type I Cell Injury in Acute Lung Injury. Am. J. Respir. Crit. Care Med.173 (9), 1008–1015. 10.1164/rccm.200509-1477OC
141
UhalB. D.NguyenH. (2013). The Witschi Hypothesis Revisited after 35 years: Genetic Proof from SP-C Brichos Domain Mutations. Am. J. Physiol. Lung Cel. Mol. Physiol.305 (12), L906–L911. 10.1152/ajplung.00246.2013
142
UmsteadT. M.HewageE. K.MathewsonM.BeaudoinS.ChroneosZ. C.WangM.et al (2020). Lower Respiratory Tract Delivery, Airway Clearance, and Preclinical Efficacy of Inhaled GM-CSF in a Postinfluenza Pneumococcal Pneumonia Model. Am. J. Physiol. Lung Cel. Mol. Physiol.318 (4), L571–L579. 10.1152/ajplung.00296.2019
143
UnkelB.HoegnerK.ClausenB. E.Lewe-SchlosserP.BodnerJ.GattenloehnerS.et al (2012). Alveolar Epithelial Cells Orchestrate DC Function in Murine Viral Pneumonia. J. Clin. Invest.122 (10), 3652–3664. 10.1172/JCI62139
144
VaillancourtM.JorthP. (2020). The Unrecognized Threat of Secondary Bacterial Infections with COVID-19. mBio11 (4), e01806–e01820. 10.1128/mBio.01806-20
145
VegaM. A.Simón-FuentesM.González de la AlejaA.NietoC.ColmenaresM.HerreroC.et al (2020). MAFB and MAF Transcription Factors as Macrophage Checkpoints for COVID-19 Severity. Front. Immunol.11 (2958), 603507. 10.3389/fimmu.2020.603507
146
WangP.LuoR.ZhangM.WangY.SongT.TaoT.et al (2020). A Cross-Talk between Epithelium and Endothelium Mediates Human Alveolar-Capillary Injury during SARS-CoV-2 Infection. Cel. Death. Dis.11 (12), 1042. 10.1038/s41419-020-03252-9
147
WeberG. F.ChoustermanB. G.HilgendorfI.RobbinsC. S.TheurlI.GerhardtL. M.et al (2014). Pleural Innate Response Activator B Cells Protect against Pneumonia via a GM-CSF-IgM axis. J. Exp. Med.211 (6), 1243–1256. 10.1084/jem.20131471
148
WessendarpM.Watanabe-ChaillandM.LiuS.StankiewiczT.MaY.ShimaK.et al (2022). Role of GM-CSF in Regulating Metabolism and Mitochondrial Functions Critical to Macrophage Proliferation. Mitochondrion. 62, 85–101. 10.1016/j.mito.2021.10.009
149
WestphalenK.GusarovaG. A.IslamM. N.SubramanianM.CohenT. S.PrinceA. S.et al (2014). Sessile Alveolar Macrophages Communicate with Alveolar Epithelium to Modulate Immunity. Nature506 (7489), 503–506. 10.1038/nature12902
150
WittekindtO. H. (2017). Tight Junctions in Pulmonary Epithelia during Lung Inflammation. Pflugers Arch.469 (1), 135–147. 10.1007/s00424-016-1917-3
151
WongM. H.ChapinO. C.JohnsonM. D. (2012). LPS-stimulated Cytokine Production in Type I Cells Is Modulated by the Renin-Angiotensin System. Am. J. Respir. Cel. Mol. Biol.46 (5), 641–650. 10.1165/rcmb.2011-0289OC
152
YamamotoK.FerrariJ. D.CaoY.RamirezM. I.JonesM. R.QuintonL. J.et al (2012). Type I Alveolar Epithelial Cells Mount Innate Immune Responses during Pneumococcal Pneumonia. J. Immunol.189 (5), 2450–2459. 10.4049/jimmunol.1200634
153
YuX.ButtgereitA.LeliosI.UtzS. G.CanseverD.BecherB.et al (2017). The Cytokine TGF-β Promotes the Development and Homeostasis of Alveolar Macrophages. Immunity47 (5), 903–912. 10.1016/j.immuni.2017.10.007
154
ZhanY.LewA. M.ChopinM. (2019). The Pleiotropic Effects of the GM-CSF Rheostat on Myeloid Cell Differentiation and Function: More Than a Numbers Game. Front. Immunol.10, 2679. 10.3389/fimmu.2019.02679
Summary
Keywords
GM-CSF, alveolar macrophage, granulocyte-macrophage colony-stimulating factor, sargramostim, COVID-19, acute respiratory distress syndrome, immune response, respiratory infections
Citation
McCormick TS, Hejal RB, Leal LO and Ghannoum MA (2022) GM-CSF: Orchestrating the Pulmonary Response to Infection. Front. Pharmacol. 12:735443. doi: 10.3389/fphar.2021.735443
Received
02 July 2021
Accepted
13 December 2021
Published
17 January 2022
Volume
12 - 2021
Edited by
Jacobo Sellares Torres, Hospital Clinic of Barcelona, Spain
Reviewed by
Burton F. Dickey, University of Texas MD Anderson Cancer Center, United States
Antonio Molino, University of Naples Federico II, Italy
Updates
Copyright
© 2022 McCormick, Hejal, Leal and Ghannoum.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mahmoud A. Ghannoum, mag3@case.edu
This article was submitted to Respiratory Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.